• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Avedro Inc.

Glaukos completes Avedro buy

November 21, 2019 By Danielle Kirsh

Glaukos logo

Glaukos (NYSE:GKOS) today said it completed its acquisition of Avedro for an undisclosed amount. Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus. “Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” […]

Filed Under: Featured, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: Avedro Inc., Glaukos

On mixed Q2 results, Glaukos announces Avedro buy

August 8, 2019 By Sarah Faulkner

Glaukos logo

Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Avedro Inc., Glaukos

Avedro application needs more work, FDA says

March 18, 2014 By drugdelivery

Avedro application need more work, FDA says

Massachusetts ophthalmic devices maker Avedro has some issues to address before the company can move forward with an FDA New Drug Application for its light-based cross-linking product for treatment.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Avedro Inc., New Drug Application (NDA)

New FDA rules imperil Bioject | Wall Street Beat

April 3, 2012 By drugdelivery

MassDevice.com Wall Street Beat

Bioject (OTC:BJCT) said it’s unsure of its ability to stay afloat after the FDA instituted new rules last year governing jet injection of vaccines, which accounts for about 70% of Bioject’s business, according to a regulatory filing.

Filed Under: Contract Services, Drug-Device Combinations Tagged With: Athersys Inc., Avedro Inc., Barclay's, Bioject Medical Technologies Inc., Deals Roundup, EnteroMedics Inc., Hoya Vision, Maquet Cardiovascular LLC, Misonix Inc., Optos Inc., Siemens

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS